228 related articles for article (PubMed ID: 35045416)
1. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Grünwald V; Hilser T; Meiler J; Goebell PJ; Ivanyi P; Strauss A; Hartmann A; Bedke J; Bergmann L
Oncol Res Treat; 2022; 45(5):272-280. PubMed ID: 35045416
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
6. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
Calvani N; Morelli F; Chiuri V; Gnoni A; Scavelli C; Fedele P; Orlando L; Maiello E; Lorusso V; Cinieri S
Med Oncol; 2013; 30(2):578. PubMed ID: 23613183
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
9. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
Ravaud A; Barrios CH; Alekseev B; Tay MH; Agarwala SS; Yalcin S; Lin CC; Roman L; Shkolnik M; Anak O; Gogov S; Pelov D; Louveau AL; Melichar B
Ann Oncol; 2015 Jul; 26(7):1378-84. PubMed ID: 25851632
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
Signorovitch JE; Vogelzang NJ; Pal SK; Lin PL; George DJ; Wong MK; Liu Z; Wang X; Culver K; Scott JA; Jonasch E
Curr Med Res Opin; 2014 Nov; 30(11):2343-53. PubMed ID: 25105304
[TBL] [Abstract][Full Text] [Related]
12. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Grünwald V; Ivanyi P; Zschäbitz S; Wirth M; Staib P; Schostak M; Dargatz P; Müller L; Metz M; Bergmann L; Steiner T; Welslau M; Lorch A; Rafiyan R; Hellmis E; Darr C; Schütt P; Meiler J; Kretz T; Loidl W; Flörcken A; Mänz M; Hinke A; Hartmann A; Grüllich C
Eur Urol; 2023 Dec; 84(6):571-578. PubMed ID: 37758574
[TBL] [Abstract][Full Text] [Related]
15. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
[TBL] [Abstract][Full Text] [Related]
17. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
[TBL] [Abstract][Full Text] [Related]
20. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
